Genetic intestinal polyposis

Genetic intestinal polyposis (Orphanet code 363314) is a group classification encompassing inherited conditions characterized by the development of multiple polyps in the gastrointestinal tract, primarily the intestines. This category includes several well-known syndromes such as familial adenomatous polyposis (FAP), MUTYH-associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, and other hereditary polyposis conditions. These disorders are caused by germline mutations in various genes that regulate cell growth and differentiation in the gastrointestinal epithelium. The primary body system affected is the gastrointestinal tract, where polyps can develop throughout the stomach, small intestine, and colon. Depending on the specific subtype, polyps may be adenomatous, hamartomatous, or serrated in nature. Key clinical features across these conditions include rectal bleeding, abdominal pain, changes in bowel habits, anemia due to chronic blood loss, and a significantly elevated risk of colorectal cancer if left untreated. Some subtypes also carry increased risks for extraintestinal cancers and may present with additional features such as osteomas, skin lesions, or pigmented macules. Management of genetic intestinal polyposis conditions typically involves regular endoscopic surveillance beginning at an age determined by the specific syndrome, polypectomy to remove polyps, and in some cases prophylactic colectomy to reduce colorectal cancer risk. Genetic counseling and cascade genetic testing of at-risk family members are essential components of care. Chemoprevention strategies, including the use of COX-2 inhibitors or aspirin, have been studied in certain subtypes, though surgical management remains the cornerstone of cancer prevention in high-risk patients.

Common questions about Genetic intestinal polyposis